AU1722300A - Chlamydia pneumoniae genome sequence - Google Patents

Chlamydia pneumoniae genome sequence

Info

Publication number
AU1722300A
AU1722300A AU17223/00A AU1722300A AU1722300A AU 1722300 A AU1722300 A AU 1722300A AU 17223/00 A AU17223/00 A AU 17223/00A AU 1722300 A AU1722300 A AU 1722300A AU 1722300 A AU1722300 A AU 1722300A
Authority
AU
Australia
Prior art keywords
genome sequence
chlamydia pneumoniae
pneumoniae genome
chlamydia
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17223/00A
Inventor
Ronald Davis
Sue Kalman
Wayne Mitchell
Richard Stephens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU1722300A publication Critical patent/AU1722300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AU17223/00A 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence Abandoned AU1722300A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10827998P 1998-11-12 1998-11-12
US60108279 1998-11-12
US12860699P 1999-04-08 1999-04-08
US60128606 1999-04-08
PCT/US1999/026923 WO2000027994A2 (en) 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence

Publications (1)

Publication Number Publication Date
AU1722300A true AU1722300A (en) 2000-05-29

Family

ID=26805735

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17223/00A Abandoned AU1722300A (en) 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence

Country Status (5)

Country Link
EP (1) EP1133572A4 (en)
JP (1) JP2002529069A (en)
AU (1) AU1722300A (en)
CA (1) CA2350775A1 (en)
WO (1) WO2000027994A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463097A (en) 1996-01-04 1997-08-01 Rican Limited Helicobacter pylori bacterioferritin
EP1105490A1 (en) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
CA2340283A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding pomp91a protein of chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094340A1 (en) 1998-12-01 2002-07-18 Andrew D. Murdin Chlamydia antigens and corresponding dna thereof
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (en) 1998-12-08 2008-01-30 科里克萨有限公司 Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
EP1140999A1 (en) 1998-12-23 2001-10-10 Aventis Pasteur Limited $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2356057A1 (en) 1998-12-28 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
ATE417106T1 (en) 1999-03-12 2008-12-15 Aventis Pasteur CHLAMYDIA ANTIGENS AND THEIR CORRESPONDING DNA FRAGMENTS AND USES THEREOF
CA2368374A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 47 human secreted proteins
EP1165828A4 (en) * 1999-03-26 2002-09-25 Human Genome Sciences Inc 50 human secreted proteins
CA2373021A1 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP4667694B2 (en) 1999-09-20 2011-04-13 サノフィ、パストゥール、リミテッド Chlamydia antigen and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ES2303525T3 (en) 2000-04-21 2008-08-16 Corixa Corporation COMPOUNDS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF INFECTION BY CHLAMYDIA.
CA2408199A1 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
DE60139690D1 (en) * 2000-07-03 2009-10-08 Novartis Vaccines & Diagnostic IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7537772B1 (en) 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
US20030059896A1 (en) * 2000-12-21 2003-03-27 Shire Biochem Inc. Novel chlamydia antigens and corresponding DNA fragments
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP2335723A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
BR0315767A (en) 2002-11-01 2005-09-06 Glaxosmithkline Biolog Sa Immunogenicity composition, method for making a vaccine, kit, vaccine, container with a water repellent inner surface, and method for preserving a composition comprising ipv and a stabilizing agent
PT2279746E (en) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ES2596553T3 (en) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Immunogenic compositions based on microparticles comprising adsorbed toxoid and an antigen containing a polysaccharide
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
JP2008508320A (en) 2004-07-29 2008-03-21 カイロン コーポレイション Immunogenic composition against gram positive bacteria such as STREPTOCOCCUSAGALACTIAE
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1858920B1 (en) 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
SG164344A1 (en) 2005-02-18 2010-09-29 Novartis Vaccines & Diagnostics Srl Immunogens from uropathogenic escherichia coli
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
ES2561483T3 (en) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa GAS57 mutant antigens and GAS57 antibodies
KR101773114B1 (en) 2007-12-21 2017-08-30 노파르티스 아게 Mutant forms of streptolysin o
AU2009309416B2 (en) 2008-10-27 2015-05-28 Glaxosmithkline Biologicals S.A. Purification method
US20110293664A1 (en) * 2008-12-17 2011-12-01 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
CN102307477B (en) 2009-01-05 2015-07-29 埃皮托吉尼西斯股份有限公司 Adjunvant composition and using method
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
EP3549602A1 (en) 2009-03-06 2019-10-09 GlaxoSmithKline Biologicals S.A. Chlamydia antigens
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
EP3199177A1 (en) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
KR20130121699A (en) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 Interactive hybrid asynchronous computer game infrastructure
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20120135025A1 (en) * 2010-10-20 2012-05-31 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
CA2839507A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
CN103917245B (en) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 Method for preparing glycoprotein glycoconjugate
CN104080479B (en) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 Carrier molecules including spr0096 and spr2021 antigen
MX2014014067A (en) 2012-05-22 2015-02-04 Novartis Ag Meningococcus serogroup x conjugate.
BE1024634B1 (en) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. IMMUNOGENIC COMPOSITIONS
CN108514870B (en) * 2018-04-27 2020-02-28 湖南大学 Hydrotalcite-poly (m-phenylenediamine) composite material and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374718A (en) * 1992-08-26 1994-12-20 Gen-Probe Incorporated Nucleic acid probes to chlamydia pneumoniae
JPH08294400A (en) * 1995-04-28 1996-11-12 Hitachi Chem Co Ltd Probe and primer for detecting and measuring chlamydia pneumoniae gene, detection and measurement of chlamydia pneumoniae gene using the same probe or primer and reagent for detecting and measuring chlamydia pneumoniae gene containing the same probe or primer
JPH10210978A (en) * 1997-01-31 1998-08-11 Hitachi Chem Co Ltd Recombinant vector and transformant containing the same, and recombinant vacurovirus and its production, and production of chlamydia pneumoniae antigen polypeptide

Also Published As

Publication number Publication date
JP2002529069A (en) 2002-09-10
EP1133572A2 (en) 2001-09-19
WO2000027994A3 (en) 2000-11-23
WO2000027994A2 (en) 2000-05-18
CA2350775A1 (en) 2000-05-18
EP1133572A4 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
AU1722300A (en) Chlamydia pneumoniae genome sequence
AU9277698A (en) 9-amino-3-keto erythromycin derivatives
AU4962499A (en) Solid state microanemometer
AU4289399A (en) Nucleic acid transfer phage
AU6417799A (en) Matrix-remodeling genes
AUPP210698A0 (en) Fin
AU5044299A (en) Multipurpose support
AU8925398A (en) 3-descladinose 6-o-substituded erythromycin derivatives
AU6266399A (en) Tip-plate thermocouple
AU2001235616A1 (en) Immunostimulatory oligonucleotides
AU743869C (en) Lehr loader pusher bar assembly
AU1504899A (en) Erythromycin derivatives
AU1161500A (en) Macrolide intermediates
AU6217199A (en) Compositions
AUPP247498A0 (en) Improved palletizer
AUPP786998A0 (en) Hand implement
AU1775500A (en) Circuit-breaker
AU4513599A (en) Nucleotide sequence
AU1055399A (en) Rollerboard
AU5314999A (en) Modified oligonucleotides
AU1396100A (en) Oligonucleotide conjugation
AU2001235617A1 (en) Immunostimulatory oligonucleotides
AUPP728898A0 (en) Immunostimulatory dna
AU5752299A (en) Chemical compositions
AU4831199A (en) Erythromycin compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase